| 摘要 |
This invention provides a replication-deficient adenovirus type 5 expression vector which comprises an adenovirus genome having a deletion in the E1 and E3 region of the genome and an insertion within the region of a nucleic acid encoding a cytochrome 2C9 p450, cytochrome 3A4 p450, or NADPH cytochrome p450 reductase under the control of a Rous Sarcoma Virus promoter. This invention provides a method of inducing chemotoxicity of a tumor cell comprising, transfecting the tumor cell with the replication-deficient adenovirus type 5 expression vectors and therafter a prodrug, whereby the cells are selectively killed, thereby inducing chemotoxicity of the tumor cell. This invention provides a method of treating a subject with cancer comprising administering to the subject a therapeutically effective amount of: a pharmaceutical composition comprising a replication-deficient adenovirus type 5 expression vectors; and a prodrug, or a vector comprising a nucleic acid encoding a prodrug, and suitable carrier or diluent, whereby tumor cells of the subject are selectively killed, thereby treating the subject with cancer. |
